NCT01357759 - Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions

Rheumatoid Arthritis

Interventions

DRUG

MORAb-022

IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.; IV infusion of Placebo (saline)

DRUG

MORAb-022

IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.; IV infusion of Placebo (saline)

Trial Locations (5)

16635

Altoona Center for Clinical Research, Duncansville

32256

Seaview Jacksonville, LLC, Jacksonville

73112

Lynn Health Science Institute, Oklahoma City

90036

Axis Clinical Trials, Los Angeles

Unknown

Pharmaceutical Research Associates Group B.V., Zuidlaren